BIOVIE INC. (BIVI)
Data as of , from SEC Form 4 filings.
See up to 3 months of BIVI. The 7-day demo opens the 1M and 3M ranges and puts BIVI on your watchlist.
Start 7-day demoLatest BIVI insider trades
Joseph M. Palumbo - OfficerOpen-market purchase$10K- Amy Suzon Chappell - Director
About BIOVIE INC. (BIVI)
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
- CARSON CITY, NV
- 13
- 2014
- Nasdaq
BIVI Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 23,280 | $49K |
BIVI insider transactions (Form 4)
1713 Form 4 filings on record, the earliest from Aug 7, 2025, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Joseph M. Palumbo - Officer | Open-market purchase | Common Stock | 4,843 | $2.16 footnote F1 | $10K | |
| ||||||
| Amy Suzon Chappell - Director | Open-market purchase | Common Stock | 727 footnote F1 | $2.16 | $2K | |
| ||||||
| Joanne Wendy Kim - Officer | Open-market purchase | Common Stock | 2,500 footnote F1 | $2.18 | $5K | |
| ||||||
| Cuong V. Do - Officer | Open-market purchase | Common Stock | 15,210 | $2.08 footnote F1 | $32K | |
| ||||||
| Joseph M. Palumbo - Officer | Grant or award | Stock Option (right to buy) | 132,000 | $0.00 | - | |
| Joanne Wendy Kim - Officer | Grant or award | Stock Option (right to buy) | 110,100 | $0.00 | - | |
| Sigmund Rogich - Director | Grant or award | Stock Option (right to buy) | 70,000 | $0.00 | - | |
| Sigmund Rogich - Director | Grant or award | Stock Option (right to buy) | 141,100 | $0.00 | - | |
| Cuong V. Do - Officer | Grant or award | Stock Option (right to buy) | 665,300 | $0.00 | - | |
| Michael Edward Sherman - Director | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Michael Edward Sherman - Director | Grant or award | Stock Option (right to buy) | 341,100 | $0.00 | - | |
| Kameel D. Farag - Director | Grant or award | Stock Option (right to buy) | 57,500 | $0.00 | - | |
| Amy Suzon Chappell - Director | Grant or award | Stock Option (right to buy) | 57,500 | $0.00 | - | |
| James Paul Lang - Director | Grant or award | Stock Option (right to buy) | 90,000 | $0.00 | - | |
| James Paul Lang - Director | Grant or award | Stock Option (right to buy) | 330,500 | $0.00 | - | |
| Cuong V. Do - Officer | Open-market purchase | Common Stock | 5,000 | - | - | |
| Cuong V. Do - Officer | Open-market purchase | Warrants (right to buy) | 5,000 | - | - | |
BIVI insider trading FAQ
What is the latest insider trade for BIVI?
BIOVIE INC. (BIVI) had 4 insider filings in the last 90 days, with the most recent on 29 August 2026. The full record for BIVI runs to 13 Form 4 filings, the earliest from 7 August 2025. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BIVI stock?
4 insider purchases of BIVI were filed in the last 90 days, totaling $49K.
How many insiders are selling BIVI stock?
No insider sales of BIVI were filed in the last 90 days.
Where can I see BIVI SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BIVI Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Joseph M. Palumbo view on EDGAR
- - Amy Suzon Chappell view on EDGAR
- - Joanne Wendy Kim view on EDGAR
- - Cuong V. Do view on EDGAR
- - Joseph M. Palumbo view on EDGAR
- - Joanne Wendy Kim view on EDGAR
- - Sigmund Rogich view on EDGAR
- - Cuong V. Do view on EDGAR
- - Michael Edward Sherman view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where BIVI's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BIVI with a 7-day demo
- BIVI on your watchlist
- Every BIVI Form 4 filing on record
- Up to 3 months of BIVI price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
